Literature DB >> 11050389

A 'non-canonical' DNA-binding element mediates the response of the Fas-ligand promoter to c-Myc.

S Kasibhatla1, H M Beere, T Brunner, F Echeverri, D R Green.   

Abstract

Cell number is regulated by maintaining a balance between cell proliferation and cell death through apoptosis. Key regulators of this balance include the oncogene product c-Myc, which promotes either entry into the cell cycle or apoptosis [1]. Although the mechanism of c-Myc-induced apoptosis remains unclear, it is susceptible to regulation by survival factors [2,3] and can proceed through the interaction of Fas ligand (FasL) with its receptor, Fas [4]. Activated T lymphocytes are eliminated by an apoptotic process known as activation-induced cell death (AICD), which requires the transcriptional induction of FasL expression [5-7] and sustained levels of c-Myc [8]. The FasL promoter can be driven by c-Myc overexpression, and functional inhibitors of Myc and its binding partner, Max, inhibit the transcriptional activity of the FasL promoter [9,10]. We identified a non-canonical binding site (ATTCTCT) for c-Myc-Max heterodimers in the FasL promoter, which, when mutated, abolished activity in response to c-Myc. Exchange of the canonical c-Myc responsive elements (CACGTG) in the ornithine decarboxylase (ODC) promoter [11] with the non-canonical sequence in the FasL promoter generated an ODC-FasL promoter that was significantly more responsive to c-Myc than the wild-type ODC promoter. Our findings identify a precise physiological role for c-Myc in the induction of apoptosis as a transcriptional regulator of the FasL gene.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11050389     DOI: 10.1016/s0960-9822(00)00727-2

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  8 in total

1.  Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma.

Authors:  Colleen T Harrington; Elena Sotillo; Aude Robert; Katharina E Hayer; Agata M Bogusz; James Psathas; Duonan Yu; Deanne Taylor; Chi V Dang; Peter S Klein; Michael D Hogarty; Birgit Geoerger; Wafik S El-Deiry; Joëlle Wiels; Andrei Thomas-Tikhonenko
Journal:  Leukemia       Date:  2019-03-26       Impact factor: 11.528

2.  Activation of the Extrinsic and Intrinsic Apoptotic Pathways in Cerebellum of Kindled Rats.

Authors:  Carmen Rubio; César Mendoza; Cristina Trejo; Verónica Custodio; Moisés Rubio-Osornio; Leonardo Hernández; Emmanuel González; Carlos Paz
Journal:  Cerebellum       Date:  2019-08       Impact factor: 3.847

Review 3.  Tilting MYC toward cancer cell death.

Authors:  Colleen T Harrington; Elena Sotillo; Chi V Dang; Andrei Thomas-Tikhonenko
Journal:  Trends Cancer       Date:  2021-09-02

4.  Irod/Ian5: an inhibitor of gamma-radiation- and okadaic acid-induced apoptosis.

Authors:  Tone Sandal; Linda Aumo; Lars Hedin; Bjørn T Gjertsen; Stein O Døskeland
Journal:  Mol Biol Cell       Date:  2003-04-17       Impact factor: 4.138

5.  The role of MAPK-ERK pathway in 67-kDa laminin receptor-induced FasL expression in human cholangiocarcinoma cells.

Authors:  Shi-Gang Duan; Long Cheng; Da-Jiang Li; Jin Zhu; Yan Xiong; Xiao-Wu Li; Shu-Guang Wang
Journal:  Dig Dis Sci       Date:  2010-01-26       Impact factor: 3.199

6.  Lithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signalling.

Authors:  Sheng Han; Lingxuan Meng; Yang Jiang; Wen Cheng; Xinxin Tie; Junzhe Xia; Anhua Wu
Journal:  Br J Cancer       Date:  2017-03-30       Impact factor: 7.640

7.  Liver receptor homolog-1 (NR5a2) regulates CD95/Fas ligand transcription and associated T-cell effector functions.

Authors:  Juliane Schwaderer; Ann-Kathrin Gaiser; Truong San Phan; M Eugenia Delgado; Thomas Brunner
Journal:  Cell Death Dis       Date:  2017-04-13       Impact factor: 8.469

8.  Molecular analysis of Annexin expression in cancer.

Authors:  Tobias Hein; Peter H Krammer; Heiko Weyd
Journal:  BMC Cancer       Date:  2022-09-19       Impact factor: 4.638

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.